| bimatoprost / Generic mfg. |
NCT03419715: Topical Bimatoprost in the Treatment of Migraine |
|
|
| Unknown status | 2a | 70 | US | Bimatoprost Topical Solution, Lumigan, Control, placebo | Manistee Partners | Migraine Disorders, Headache Disorders | 04/19 | 06/19 | | |
NCT00651859: Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | 2 | 111 | US | Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, LUMIGAN®, Bimatoprost Vehicle Ophthalmic Solution | Allergan | Glaucoma, Ocular Hypertension | 01/04 | 01/04 | | |
NCT00652496: Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension |
|
|
| Completed | 2 | 249 | US | Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution, Bimatoprost 0.02% ophthalmic solution, Bimatoprost 0.03% ophthalmic solution, LUMIGAN® | Allergan | Glaucoma, Ocular Hypertension | 05/05 | 05/05 | | |
NCT00538304: A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension |
|
|
| Completed | 2 | 222 | US | bimatoprost eye drops, placebo | Allergan | Glaucoma, Ocular Hypertension | 05/08 | 05/08 | | |
NCT01016691: Safety and Efficacy of a Drug Delivery System in Glaucoma |
|
|
| Completed | 2 | 47 | US | High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03% | Vistakon Pharmaceuticals | Open-angle Glaucoma, Ocular Hypertension | 02/10 | | | |
NCT01001195: Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution |
|
|
| Completed | 2 | 165 | US | AGN-210669 ophthalmic solution, 0.1%, AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, bimatoprost ophthalmic solution 0.03%, LUMIGAN® | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 04/10 | 04/10 | | |
NCT01064882: Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence |
|
|
| Completed | 2 | 104 | US | bimatoprost ophthalmic solution 0.005%, bimatoprost ophthalmic solution 0.015%, bimatoprost ophthalmic solution 0.03%, LATISSE® | Allergan | Eyelash Hypotrichosis | 07/10 | 07/10 | | |
NCT02170662: Topical Bimatoprost Effect on Androgen Dependent Hair Follicles |
|
|
| Completed | 2 | 33 | US | Bimatoprost, Placebo | Duke University | Male Pattern Hair Loss, Androgenetic Alopecia | 05/11 | 05/11 | | |
NCT01110499: Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension |
|
|
| Completed | 2 | 163 | US | AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3, AGN-210961 Formulation 4, AGN-210961 Formulation 5, AGN-210961 Formulation 6, AGN-210961 Formulation 7, bimatoprost ophthalmic solution 0.03%, LUMIGAN® | Allergan | Ocular Hypertension, Primary Open-Angle Glaucoma | 05/11 | 06/11 | | |
NCT01291108: Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Completed | 2 | 125 | US | AGN-210669, bimatoprost, LUMIGAN®, bimatoprost vehicle | Allergan | Glaucoma, Open-Angle, Ocular Hypertension | 10/11 | 10/11 | | |
| Completed | 2 | 306 | US, Europe | bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 2% solution, Rogaine®, Regaine® | Allergan | Alopecia, Baldness | 07/12 | 09/12 | | |
| Completed | 2 | 307 | US, Europe | bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C, bimatoprost vehicle solution, minoxidil 5% solution, Rogaine®, Regaine® | Allergan | Alopecia, Alopecia, Androgenetic, Baldness | 08/12 | 09/12 | | |
NCT01904721: A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) |
|
|
| Completed | 2 | 244 | US | Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle | Allergan | Alopecia, Alopecia, Androgenetic, Baldness | 09/14 | 01/15 | | |
CMO, NCT03292796: RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery. |
|
|
| Completed | 2 | 56 | Europe | Prostaglandins, Latanoprost Travaprost Bimatoprost Tafluprost | Julie Dawson | Open Angle Glaucoma and Cataract | 10/19 | 07/20 | | |
2017-002823-46: Efficacy and safety assessment of T4030 eye drops (unpreserved fixed combination of bimatoprost 0.01% and timolol 0.1% or 0.5%) versus Ganfort® UD (Unit Dose) in ocular hypertensive or glaucomatous patients. |
|
|
| Completed | 2 | 143 | Europe | Ganfort UD, Unpreserved fixed combination bimatoprost 0.01% and timolol 0.1% eye drops presented in unit dose, Unpreserved fixed combination bimatoprost 0.01% and timolol 0.5% eye drops presented in unit dose, T4030a, T4030c, Eye gel in single-dose container, Ganfort UD | Laboratoires THÉA; Research and Development Department, Laboratoires THEA; Research and Development Department, Laboratoires THÉA, Laboratoires THEA | Glaucoma, ocular hypertension, over tension in the eye, Body processes [G] - Ocular Physiological Phenomena [G14] | | | | |
NCT06122090: Treatment of Hypopigmented Scars With Bimatoprost |
|
|
| Recruiting | 2 | 25 | US | Bimatoprost, Saline | Medstar Health Research Institute, Latham Fund | Scars, Hypopigmented Scar, Hypopigmented Skin, Burn Scar, Scarring, Cicatrix, Hypertrophic, Cicatrix, Pigmentation Disorder, Burns Laser | 12/24 | 07/25 | | |
NCT00809848: Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma |
|
|
| Completed | 1/2 | 172 | US | AGN-210669 ophthalmic solution, 0.075%, AGN-210669 ophthalmic solution, 0.05%, AGN-210669 ophthalmic solution, 0.025%, bimatoprost ophthalmic solution 0.03%, Lumigan®, AGN-210669 vehicle ophthalmic solution | Allergan | Ocular Hypertension, Glaucoma | 05/09 | 05/09 | | |
NCT01157364 / 2011-005091-42: Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension |
|
|
| Completed | 1/2 | 109 | Europe, Canada, US, RoW | bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%, LUMIGAN® | Allergan | Open-Angle Glaucoma, Ocular Hypertension | 07/16 | 08/16 | | |
NCT05600673: Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata |
|
|
| Completed | 1/2 | 30 | RoW | Bimatoprost 0.03% solution, Topical treatment of skin lesions, CO2 fractional laser, laser treratment | Ahmed Hassan Nouh MD | Alopecia Areata | 01/21 | 05/21 | | |
NCT04499248: AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension |
|
|
| Recruiting | 1/2 | 96 | Japan, US | AGN-193408 SR, Lumigan, Active Comparator, Sham Administration, Lumigan Vehicle, Vehicle | AbbVie | Open-angle Glaucoma, Ocular Hypertension | 02/29 | 02/29 | | |
